{"product_id":"socazolimab","title":"Socazolimab","description":"\u003cp\u003eSocazolimab is a fully human anti-PD-L1 (programmed cell death 1 ligand 1) monoclonal antibody, an immune checkpoint inhibitor, developed by Sorrento.\u003c\/p\u003e\u003cul\u003e\u003cli\u003e\n\u003cspan data-huuid=\"5813577302449632437\"\u003eSocazolimab \u003c\/span\u003esold under the brand name 善克钰® in china.\u003c\/li\u003e\u003c\/ul\u003e\u003cp\u003eOn December 21, 2023, the official website of the China National Medical Products Administration (NMPA) announced that the anti-PD-L1 monoclonal antibody socazolimab, applied for by Zhaoke Oncology, a subsidiary of Lee's Pharmaceutical, has been officially approved for the treatment of recurrent or metastatic cervical cancer.\u003c\/p\u003e","brand":"Lee's Pharmaceutical, China","offers":[{"title":"Default Title","offer_id":44797956849707,"sku":"RL3220250101","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-01-0918.jpg?v=1787022271","url":"https:\/\/xomeds.com\/products\/socazolimab","provider":"XOMEDS","version":"1.0","type":"link"}